Collaborative Funding Partnerships

CIRM funds research carried out in California. However, excellent stem cell science is taking place worldwide. Our collaborative funding relationships facilitate work between Californian scientists and their innovative colleagues around the globe. The program provides a mechanism for funding partnerships in which CIRM funds the California scientists while our funding partners support researchers in their jurisdictions.

Collaborative funding of research groups optimizes the use of resources, avoids duplication and creates a critical mass of excellence across a wide range of specialties worldwide. For CIRM grantees, the program expands the number of scientists with whom they can work and mitigates the geographic limitations imposed by CIRM’s funding.

CIRM collaborative funder map

In the map above, countries in green indicate funding relationships with CIRM.

The list of Approved Funds (below) represents the current award amount under agreement with the grantee which can be less the amount approved by the governing board. For projects approved by the governing that have not yet been issued an award agreement, the Approved Funds will temporarily reflect the amount approved by the governing board.

Collaborative Funder RFA Approved funds
JDRF Disease Team Research I Cell Therapy for Diabetes $22,999,933
NIH Early Translational IV A drug-screening platform for autism spectrum disorders using human astrocytes $1,656,456
UK Disease Team Research I Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
UK Disease Team Therapy Development III Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors $11,650,152
Victoria, Australia Early Translational I Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease $3,599,997
Germany Tools and Technologies III Development of a clinical-grade extracorporeal liver support system using human induced pluripotent stem cell-derived hepatic cells $1,257,011
Victoria, Australia Early Translational I Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation $5,830,771
Australia Tools and Technologies III A suite of engineered human pluripotent stem cell lines to facilitate the generation of hematopoietic stem cells $1,382,400
Victoria, Australia Early Translational I Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product $5,405,397
Germany Early Translational I Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson's disease research and drug discovery $3,698,646
Germany Tools and Technologies III User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery $1,784,052
Japan Basic Biology II Role of the microenvironment in human iPS and NSC fate and tumorigenesis $1,256,194
Victoria, Australia Early Translational I Developmental Candidates for Cell-Based Therapies for Parkinson's Disease (PD) $5,190,752
Australia Tools and Technologies III Optimizing the differentiation and expansion of microglial progenitors from human pluripotent stem cells for the study and treatment of neurological disease. $1,147,596
Maryland Early Translational II Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury $1,517,767
Victoria, Australia Transplantation Immunology Thymus based tolerance to stem cell therapies $1,108,921
Germany Early Translational II Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
Victoria, Australia Transplantation Immunology “Engineered immune tolerance by Stem Cell-derived thymic regeneration” $1,271,729
Maryland Early Translational II Banking transplant ready dopaminergic neurons using a scalable process $4,983,013
Germany Basic Biology III Characterization and Engineering of the Cardiac Stem Cell Niche $1,116,331
Germany Early Translational II Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds $4,635,576
Germany Early Translational III Heart Repair with Human Tissue Engineered Myocardium $4,397,241
Germany Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $2,756,536
Australia Early Translational III Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells $4,590,219
Germany Early Translational II Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model $2,472,839
China Early Translational III Generation of safe and therapeutically effective human induced hepatocyte-like cells $1,544,170
Canada Disease Team Research I Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) $19,999,826
NIH Disease Team Therapy Development - Research Genetic Re-programming of Stem Cells to Fight Cancer $19,875,776
Germany Disease Team Research I Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $17,244,851
Andalusia, Spain Disease Team Therapy Development - Research Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia $3,731,362
NIH iPSC Consortia Award The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development $300,000
UK Disease Team Research I Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells $18,759,276

Workshop Reports